Davunetide vs Semax

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Semax is believed to upregulate brain-derived neurotrophic factor (BDNF) and other neuroprotective factors, enhancing neuronal survival and synaptic plasticity. It modulates the dopaminergic and serotonergic systems, contributing to its reported effects on mood and focus. Its mechanism of action differs from classical stimulants — it does not act on adrenergic receptors and does not produce typical stimulant tolerance or dependence patterns.

Semax (MEHFPGP) is a synthetic heptapeptide derived from the N-terminal fragment of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension to enhance stability, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a nootropic and neuroprotective agent, and registered in Russia as a pharmaceutical for cognitive disorders, ischemic stroke, and cerebrovascular insufficiency. Semax modulates BDNF and NGF expression in neural tissue, influences dopaminergic, serotonergic, and cholinergic activity, and is proposed to exert neuroprotective effects in ischemic conditions by reducing neuroinflammation and supporting neuronal survival following cerebrovascular events. Human clinical studies published in peer-reviewed Russian neurology journals (Zh Nevrol Psikhiatr Im S.S. Korsakova) — indexed in PubMed — have examined semax in ischemic stroke patients and cerebrovascular insufficiency, reporting improvements in neurological outcomes and cognitive function; these studies document genuine clinical investigation, though no blinded Western RCTs or external replications exist. Semax is approved in Russia for clinical use in ischemic stroke and cognitive disorders; it has no FDA approval and is not approved in any Western jurisdiction, and while the Russian clinical evidence reflects substantial investigational work, the absence of independently conducted Western trials limits confidence in translating the reported findings to broader clinical recommendations. Semax is available in both standard and N-acetyl semax (N-acetyl-Semax) formulations; N-acetyl semax is considered to have enhanced lipophilicity and potentially extended biological activity, though direct comparative clinical data between formulations is limited. Intranasal administration — semax nasal spray — is the primary delivery route in Russian clinical practice and the form used in the published clinical research, offering rapid mucosal absorption and CNS delivery. Semax nasal spray formulations at 0.1% and 1% concentrations have been used in the Russian clinical program for stroke and cognitive disorder indications; subcutaneous injection is more common in international research compound contexts.